Document is current

Article History

Received: 16 December 2024

Accepted: 7 April 2025

First Online: 12 May 2025

Declarations

:

: Sean Khozin is co-founder and Principal at Phyusion, LLC, providing advisory services to life sciences companies. Nancy Dreyer is Principal at Dreyer Strategies LLC and has received honoraria for consulting from Pfizer. Raymond Liu has received research funding (to institute) from AstraZeneca, Biotheranostics, Beigene, Exact Sciences, and Genentech. Peter Neumann has received honoraria for consulting from Pfizer. Nathan Nussbaum is an employee of and has equity ownership in Verily Life Sciences, and stock ownership in Roche. Joyce O'Shaughnessy has received honoraria for consulting and/or advisory boards from AbbVie Inc., Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, LillyLoxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, and Veru. Debra Patt has received honoraria for educational consulting from Daiichi Sankyo, Inc. and Pfizer, and holds a leadership role at McKesson Specialty Health. Mothaffar Rimawi has received honoraria for consulting from Novartis, Pfizer, AstraZeneca, Gilead, and Sermonix. Hope Rugo has received honoria for consulting and/or advisory from NAPO, PUMA, and Sanofi Aventis; honoraria from Mylan/Viatrix and Chugai; and institutional research support from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, and Ambryx. Sara Tolaney has received honoraria for consulting and/or advisory role from Novartis, Pfizer/SeaGen, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gilead, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, Sumitovant Biopharma, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Bio, Bayer, Incyte Corp, Jazz Pharmaceuticals, Natera, Tango Therapeutics, Systimmune, eFFECTOR, Hengrui USA, Cullinan Oncology, Circle Pharma, Arvinas, BioNTech; research funding (all to institute) from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Gilead, Seattle Genetics, OncoPep, Daiichi Sankyo, Menarini/Stemline; and travel support from Eli Lilly, Sanofi, Gilead, Jazz, and BioNTech. Adam Brufsky has received honoraria for consulting from AstraZeneca, Novartis, Lilly, Genetech/Roche, Daiichi Sankyo, Merck, Agendia, Sanofi, Pfizer, Puma, Myriad, Gilead, and Bria Cell; and research support from Agendia and AstraZeneca. Dominic Galante and Marisa Weiss have nothing to disclose. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

: This article does not contain any new studies with human participants or animals performed by any of the authors. All members of the Think Tank were fully informed and consented to their thoughts being formulated into a manuscript, and invited to contribute as authors on this article (of which, 13 of the 14 members accepted).